其他
我国制剂国际化2018年Q1，对美出口过9000万美元
1.近期，FDA批准齐鲁制药集团齐鲁天和惠世公司生产的注射用哌拉西林钠他唑巴坦钠（邦达）的上市申请。
其中一个规格如下：
Active Ingredient: PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
Proprietary Name: PIPERACILLIN AND TAZOBACTAM
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL
Reference Listed Drug: No
Reference Standard: No
TE Code: AP
Application Number: A204959
Product Number: 001
Approval Date: Aug 10, 2018
Applicant Holder Full Name: QILU TIANHE PHARMACEUTICAL CO LTD
Marketing Status: Prescription
2.齐鲁制药其他的ANDA:
| Proprietary Name | Appl No |
| CEFAZOLIN SODIUM | A203661 |
| CEFEPIME HYDROCHLORIDE | A203704 |
| CEFEPIME HYDROCHLORIDE | A203704 |
| CEFEPIME HYDROCHLORIDE | A203704 |
| CEFTRIAXONE | A203702 |
| CEFTRIAXONE | A203702 |
| CEFTRIAXONE | A203702 |
| CEFTRIAXONE | A203702 |
| IRINOTECAN HYDROCHLORIDE | A203380 |
| IRINOTECAN HYDROCHLORIDE | A203380 |
| IRINOTECAN HYDROCHLORIDE | A203380 |
| OLANZAPINE | A204319 |
| OLANZAPINE | A204319 |
| OLANZAPINE | A204319 |
| OLANZAPINE | A204319 |
| OLANZAPINE | A204319 |
| OLANZAPINE | A204319 |
| ONDANSETRON HYDROCHLORIDE | A203711 |
| OXALIPLATIN | A204616 |
| OXALIPLATIN | A204368 |
| OXALIPLATIN | A204616 |
| OXALIPLATIN | A204368 |
| OXALIPLATIN | A204368 |
| PIPERACILLIN AND TAZOBACTAM | A204959 |
| PIPERACILLIN AND TAZOBACTAM | A204959 |
| PIPERACILLIN AND TAZOBACTAM | A204959 |
| TENOFOVIR DISOPROXIL FUMARATE | A209498 |
| TENOFOVIR DISOPROXIL FUMARATE | A209498 |
| TENOFOVIR DISOPROXIL FUMARATE | A209498 |
更多齐鲁制药信息，点击：
3.据中国医药保健品进出口商会：2018年一季度，中国对美国化药制剂出口额超过9000万美元，同比增长18.8%。恒瑞医药、华海药业、南通联亚、人福医药、齐鲁制药等5家位居出口前列，占制剂总出口额的67%。
欢迎关注药融圈官网
看这里：www.pharnex.com
点击文末 阅读原文 可直接进入